Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
Seizure Disorder, Hypogonadism, Erectile Dysfunction
About this trial
This is an interventional treatment trial for Seizure Disorder focused on measuring Seizure, Epilepsy, Testosterone, Hormone, Sexual Dysfunction, Hypogonadism, Men
Eligibility Criteria
Inclusion Criteria: Subject must be a male between the ages of 18 and 50 years. Subject must have localization-related epilepsy with complex partial and/or secondary generalized seizures. Subject will meet criteria for hypogonadism (abnormally low bioactive testosterone levels and abnormally low scores on questionnaires of reproductive and sexual function). Subject will have had a normal urogenital and rectal/prostate exam during the year prior to entry. Subject will have had documentation of therapeutic range serum AED levels, a normal CBC, and hepatic enzyme (ALT,AST, alkaline phosphatase) levels that are less than twofold elevated during the 6 months prior to entry. Exclusion Criteria: Subject that has taken hormones, major tranquilizers or antidepressants in the three months prior to entry.
Sites / Locations
- Beth Israel Deaconess Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
depotestosterone plus anastrozole (T-A)
depotestosterone plus placebo (T-P)
Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes an oral tablet of anastrozole 1 mg daily for the duration of the study. This group is referred to as the depotestosterone plus anastrozole (T-A) group.
Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes 1 matching placebo oral tablet daily for the duration of the study. This group is referred to as the depotestosterone plus placebo (T-P) group.